Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00507247|
Recruitment Status : Completed
First Posted : July 26, 2007
Last Update Posted : July 20, 2016
Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S. aureus bacteria with or without exchange of the central venous catheter (CVC) over guide wire in comparison with a historical control group of catheter-related S. aureus bacteremia treated with standard therapy (Vancomycin) or other active agents against staph aureus (such as beta-lactam antibiotics).
|Condition or disease||Intervention/treatment||Phase|
|Staphylococcus Aureus||Drug: Daptomycin||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Bloodstream Infections|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||September 2012|
6mg/kg/day intravenous (IV) for 10 days
6mg/kg/day IV for at least 10 days.
Other Name: Cubicin
- Clinical Response Rate [ Time Frame: 7 weeks ]Clinical response of Daptomycin administered for treatment of catheter-related bloodstream infections due to Staphylococcus Aureus bacteria, evaluated within 7 weeks of initiating Daptomycin therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507247
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Issam Raad, MD||M.D. Anderson Cancer Center|